NovoCure (NVCR) Cash & Equivalents (2014 - 2026)

NovoCure (NVCR) has reported Cash & Equivalents for 13 consecutive years, with $93.7 million the latest figure, recorded in Q2 2026.

• Quarterly Cash & Equivalents fell 37.38% year-over-year to $93.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $93.7 million (down 37.38% YoY) and the FY2025 annual result came in at $93.5 million, down 42.88% from the prior year.
• Cash & Equivalents advanced to $93.7 million in Q2 2026 per NVCR's latest filing, from $87.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for NVCR reached as high as $453.8 million in Q1 2024 and fell as low as $87.5 million in Q1 2026.
• A 5-year average of $195.4 million and a median of $164.3 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 144.01% — and 2025, when it sank 71.95%.
• Year by year, Cash & Equivalents stood at $115.3 million in 2022, then surged by 108.82% to $240.8 million in 2023, then sank by 32.0% to $163.8 million in 2024, then slumped by 42.88% to $93.5 million in 2025, then gained by 0.16% to $93.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $93.7 million, $87.5 million, and $93.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.